To include your compound in the COVID-19 Resource Center, submit it here.

MacroGenics reports Phase I data of flotetuzumab for AML

MacroGenics Inc. (NASDAQ:MGNX) reported preliminary data from 8 evaluable patients with acute myelogenous leukemia (AML) in a dose-expansion cohort of a Phase

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE